Search ARM

Oncology & Regenerative Medicine

This report provides industry specific statistics compiled from gene therapy, gene-modified cell therapy, cell therapy, and other regenerative medicine companies active in developing therapies to treat cancer and provides context for the potential of regenerative medicine to improve upon the current standard of care.

This report provides industry specific statistics compiled from gene therapy, gene-modified cell therapy, cell therapy, and other regenerative medicine companies active in developing therapies to treat cancer and provides context for the potential of regenerative medicine to improve upon the current standard of care.

As of June 2019:

There are 416+ companies worldwide working on regenerative medicine therapies in oncology, including 191 clinical-stage companies.

There are currently 132+ products in active development with 627 clinical trials ongoing, including 23 in Phase III.

Cancer causes one in six deaths worldwide, 18+ million people diagnosed with cancer each year and more than 9 million deaths attributed to cancer annually.

View Full Report

627+

Clinical trials underway
worldwide as of June 2019

PH. 1

264

PH. 2

336

PH. 3

27

Clinical Trials by Technology Type

Gene Therapy

Gene-Modified Cell Therapy

Oncolytic Virus

Cell Therapy

Clinical Trials by Indication

Companies Active in Developing Regenerative Medicines in Oncology

Financings

Global Financings for Regenerative Medicines in Oncology

Infographics

View Full Report ARM Members Active in Oncology